- 询价
- Nebulabio
- 中国
- NBL-289116
- 2025年12月23日
企业认证
相关产品推荐更多 >
重组人Bcl-XL蛋白 | Recombinant Human Bcl-XL, 1-233aa, His-tag
询价
低密度脂蛋白（LDL） | Native Human Low-Density Lipoproteins (LDL), Premium
询价
重组HMPV M/Matrix protein 蛋白 | Recombinant HMPV M/Matrix protein Protein, 1-254aa, His-tag
询价
重组人IL31蛋白 | Recombinant Human IL31, 24-164 aa, His-tag
询价
GNRHR蛋白 | Recombinant Human GNRHR, VLP
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保质期：
见COA
- 库存：
大量
- 供应商：
北京辰辉创聚生物技术有限公司
- 规格：
100ug; 500ug; 1mg; Bulk
| 产品信息
品名：NebuSelect™ Recombinant Human IgG4 Fc, 99-326aa
中文名称：重组人IgG4 Fc蛋白
别名：P01861
货号：NBL-289116
品牌：Nebulabio
规格：100UG；1MG；Bulk
| 产品描述
NebuSelect™ Recombinant Human IgG4 Fc, 99-326aa (CAT#NBL-289116) is expressed in HEK293. This recombinant protein is of high purity, verified to be greater than 95% by SDS-PAGE. Endotoxin levels are less than 1 EU/µg, as determined by the LAL (Limulus Amebocyte Lysate) assay. Please contact us freely to get bioactivity data.
| 产品属性
Species:Human
Expression System:HEK293
Molecular Weight:see COA
Target Name:IgG4 Fc, 99-326aa
Purity:＞95%
Formulation:See COA
Endotoxin:＜1 EU/ug(LAL Method)
Storage:4°C for short term. -20°C for long term.
For Research Use Only!
To get more information, please contact us freely.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Quantification of Human IgG and Related Fc Fusion Proteins by a Human IgG/Fc Capture ELISA
of recombinant human IgGs after production and purification for further assays. Here, we describe a human IgG/Fc capture enzyme linked immunosorbent assay (ELISA) which is simple, robust, inexpensive and specific for all types of human IgGs and related Fc fusion
1.FcγR的结构和分布 FcγR可分为FcγRⅠ、FcγRⅡ和FcγRⅢ三类，它们的结构和分布有所不同。 （1）FcγRⅠ（CD64）：70kDa穿膜糖蛋白，属Ig超家族成员，胞膜外区有3个C2结构，基因染色体定位于1q23～24。识别CD64的代表性McAb有McAb22、McAb32.2、197和10.1等FcγRⅠ是高亲合力受体，Kd值为10-8 ～10-9 M，主要与人的单体IgG1、IgG3以及小鼠IgG2a和IgG3结合。与人IgG4
Assessing Fc Glycan Heterogeneity of Therapeutic Recombinant Monoclonal Antibodies Using NP-HPLC
Recombinant monoclonal antibodies (rMAbs) are becoming major human therapeutics to treat life-threatening diseases such as cancer. These rMAbs are produced using either in vitro cell culture processes or transgenic technology in animals
技术资料暂无技术资料 索取技术资料
